Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in Prostate Cancer
Radiology: Imaging Cancer · 2024
DOI: 10.1148/rycan.230143 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Radiology: Imaging Cancer, 2024. Verfasst von Chenhan Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Radiology (Chenhan Hu, X.Q., Chunhong Hu, J.B., X.W.) and Pathology (R.H.), the First Affiliated Hospital of Soochow Universi…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local, Prostatectomy, Magnetic Resonance Imaging. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
To develop and validate a machine learning multimodality model based on preoperative MRI, surgical whole-slide imaging (WSI), and clinical variables for predicting prostate cancer (PCa) biochemical recurrence (BCR) following radical prostatectomy (RP). Materials and Methods In this retrospective study (September 2015 to April 2021), 363 male patients with PCa who underwent RP were divided into training (n = 254; median age, 69 years [IQR, 64-74 years]) and testing (n = 109; median age, 70 years [IQR, 65-75 years]) sets at a ratio of 7:3. The primary end point was biochemical recurrence-free survival. The least absolute shrinkage and selection operator Cox algorithm was applied to select independent clinical variables and construct the clinical signature. The radiomics signature and pathomics signature were constructed using preoperative MRI and surgical WSI data, respectively. A multimodality model was constructed by combining the radiomics signature, pathomics signature, and clinical signature. Using Harrell concordance index (C index), the predictive performance of the multimodality model for BCR was assessed and compared with all single-modality models, including the radiomics signature, pathomics signature, and clinical signature.
Results
Both radiomics and pathomics signatures achieved good performance for BCR prediction (C index: 0.742 and 0.730, respectively) on the testing cohort. The multimodality model exhibited the best predictive performance, with a C index of 0.860 on the testing set, which was significantly higher than all single-modality models (all P ≤ .01).
Conclusion
The multimodality model effectively predicted BCR following RP in patients with PCa and may therefore provide an emerging and accurate tool to assist postoperative individualized treatment. Keywords: MR Imaging, Urinary, Pelvis, Comparative Studies Supplemental material is available for this article. © RSNA, 2024.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- From the Departments of Radiology (Chenhan Hu, X.Q., Chunhong Hu, J.B., X.W.) and Pathology (R.H.), the First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou 215006, China.
ORCID-Profile: Chunhong Hu, Jie Bao, Ximing Wang
Zitieren
APA
Hu, C., Qiao, X., Huang, R., Hu, C., Bao, J., & Wang, X. (2024). Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in Prostate Cancer. Radiology: Imaging Cancer. https://doi.org/10.1148/rycan.230143
Vancouver
Hu C, Qiao X, Huang R, Hu C, Bao J, Wang X. Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in Prostate Cancer. Radiology: Imaging Cancer. 2024. doi:10.1148/rycan.230143
BibTeX
@article{Hu2024,
author = {Hu, Chenhan and Qiao, Xiaomeng and Huang, Renpeng and Hu, Chunhong and Bao, Jie and Wang, Ximing},
title = {Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in Prostate Cancer},
journal = {Radiology: Imaging Cancer},
year = {2024},
doi = {10.1148/rycan.230143}
}
EUVIMED